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Background: In this study, dosimetric aspects of TSEI consisting of a 4 MeV beam with no spoiler were investigated
in comparison to a nominal 6 MeV beam with spoiler, and the potential for clinical applications was evaluated.
Methods: The TSEI technique is based on the Stanford technique, which utilizes a beam configuration of six-dual
fields. MOSFETs were used to measure the optimal gantry angle, profile uniformity, and absolute dose at the
calibration point. The depth dose curve of the central axis was measured in the treatment plane using EBT2 film.
Photon contamination was measured as the dose at 5 cm depth in a solid water phantom relative to the maximum
dose using a parallel plate ion chamber. A MOSFET dosimeter placed on the surface of a humanoid phantom, and
EBT2 films inserted into a humanoid phantom were used to verify the TSEI commissioning.
Results: Dosimetric aspects of the 4 MeV TSEI beam, such as profile uniformity (±10%) and relative photon
contamination (<0.001%), were comparable to those of a 6 MeV TSEI beam. The relative depth dose of the 4 MeV
electrons was 81.4% at the surface and 100% at 0.4 cm. For the 6 MeV electrons, the relative depth dose was 93.4%
at the surface and 100% from 0.2 cm to 0.4 cm. The calculated B-factor of the 4 MeV TSEI beam was 1.55, and 1.53
for the 6 MeV TSEI. 80% of the prescribed dose was obtained at 0.22 cm depth for the 4 MeV TSEI beam and
0.53 cm for the 6 MeV TSEI beam in the humanoid phantom measurement.
Conclusions: The suggested 4 MeV beam for TSEI could be applied to shallow depth skin diseases and to electron
boost as second treatment course.
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Total skin electron irradiation (TSEI) was developed by
Stanford University in the 1950s and introduced for the
treatment of mycosis fungoides, the most common form
of cutaneous T-cell lymphoma which generally affects
the skin [1]. Since then, TSEI has been considered to be
one of the best treatments for mycosis fungoides and
employed for various diseases confined to the skin [2-4].
TSEI has also been extended for the treatment of other
cutaneous disease such as Kaposi’s sarcoma and sclero-
myxoedema [5-9]. The goal is to deliver a relatively uni-
form dose (e.g., ±10%) to the entire surface of the skin,* Correspondence: madangin@gmail.com
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unless otherwise stated.and not to exceed total photon contamination of 0.7 Gy
[10]. In order to deliver the treatment dose at a shallow
depth, relatively low energy electrons are considered for
TSEI, which is commonly performed with a 6 MeV beam
[11-15]. 6 MeV electrons attenuated through a beam
spoiler and air are sufficient to deliver the treatment dose
to the epidermis and dermis located at a depth of 0.5 cm
from the skin surface [16]. For 6 MeV beams the use of a
spoiler as a beam scatter-energy degrader is essential to
allow adequate skin and depth doses. Increase in surface
dose and improved profile uniformity can be obtained by
placing the spoiler in front of the patient or mounting it
on the gantry head [3,4,10,12,16]. Proper selection and
placement of a spoiler strongly influence the quality of pa-
tient treatment, since the spoiler material and position
along the beam axis are important in determining the
monitor units (MU), profile uniformity, depth dose and
relative photon contamination over the treatment plane.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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from 4 MeV to 8 MeV [17-20]. Electrons lose approxi-
mately 2 MeV/(g/cm2) while passing through the spoiler
and air at extended source to surface distance (SSD) so
that initially 6 MeV electrons arrive at the patient with an
energy of around 4 MeV [21,22].
The modified Stanford technique has been used in the
clinical implementation of TSEI [23]. Our institution im-
plemented TSEI treatment with a six-dual field technique
using 6 MeV electrons with an acrylic spoiler of 1 cm and
extended SSD of 380 cm.
In this study, TSEI consisting of a 4 MeV beam was in-
vestigated with no a spoiler and therefore had an obli-
quity factor larger than 6 MeV. This obliquity factor is
called as B factor which is ratio the treatment skin dose
to the calibration point dose for the Stanford technique
[24]. The electron energy at the treatment plane was ap-
proximately equal to that of an attenuated 6 MeV beam.
Furthermore, it reduces the photon contamination. The
comprehensive dosimetric aspects for the stated 4 MeV
technique were investigated in comparison to the nominal
6 MeV technique, and its potential for clinical application
was also investigated.
Methods
Geometric Conditions of TSEI
TSEI technique is based on the Stanford technique, which
uses a beam configuration of six-dual fields. AVarian Trilogy
linear accelerator (Varian Medical Systems, Palo Alto, CA)
generated both electron beams (4 and 6 MeV) with field
size of 34 × 34 cm2, operated under the high dose rate
mode (1000 MU/min). In our treatment room, the distance
from source to wall was 490 cm from the horizontal beam
axis. The position of the spoiler, a home-made acrylic plate
(1.05 g/cm2) of 106 × 205 × 1 cm3, was 30 cm from the
treatment plane for 6 MeV, and was not used for 4 MeV.
The SSD of 380 cm for TSEI was not influenced by scatter-
ing radiation from the walls of the treatment room. With
an SSD of 380 cm the dual field was obtained by using two
fields for which the gantry is located within ±20° to the
90° gantry angle, which is perpendicular to the treatment
plane. Figure 1 presents the patient setup and geomet-
ric conditions of the dual field technique. The MOSFET
(Best Medical Canada, Ottawa, ON) was cross-calibrated
against a NIST-traceable PTW 31013 cylindrical ion
chamber (PTW, Freiburg, Germany) in a 9 MeV elec-
tron beam, following AAPM TG-51 protocols [25].
The energy dependence of the MOSFET dosimeters
was tested before measurement. The MOSFET dosime-
ters used in this study showed reliable performance in
accordance with the results of previous studies [26].
First, the gantry angles which make the most uniform
profile of the vertical axis were determined for each
TSEI electron beam using the MOSFET measurementwith spatial resolution of 0.5° in an acrylic plate located
in the treatment plane.
Dosimetric measurements
Another home-made acrylic plate (1.05 g/cm2) of 160 ×
205 × 1 cm3 which used as total body irradiation (TBI)
treatment spoiler was applied as a phantom. The dosimetric
measurement was performed by attaching the MOSFET on
this phantom. The profile uniformity across and along the
patient’s longitudinal axis, with optimized gantry angles for
each electron beam, were investigated with spatial resolu-
tions of 2 cm and 5 cm for a central area of 40 cm, and out-
side of a central area using the MOSFET measurements,
respectively. The absolute dose at the calibration point,
which was located in treatment plane, was also defined with
MOSFET measurements.
The percentage depth dose (PDD) curve in Solid
Water™ (GAMMEX RMI, Middleton, WI) of the cen-
tral axis for the 4 MeV and 6 MeV TSEI beams was
measured for dual fields in the treatment plane using
radiochromic EBT2 film (ISP, Wayne, New Jersy, USA).
The film was inserted in the center of solid water
phantom of 10 cm parallel to the 90° gantry angle. Pho-
ton contamination for 4 MeV with no the spoiler, and
6 MeV with spoiler was measured as the dose at 5 cm
depth in a solid water phantom relative to the max-
imum dose using the Advanced Markus parallel plate
ion chamber, type M34045 (PTW, Freiburg, Germany).
In order to prevent the cable-induced effects on ion
chamber measurements in large electron fields, known
as the “Cable effect”, lead shielding of 0.5 cm thickness
was applied to the chamber cable [27].
Dosimetric commissioning and QA
Finally, with patient setup and geometric conditions of
the six dual-field technique, it is essential to determine
the multiplication factor (B-factor) for the delivered dose
at the patient surface. This factor, which relates the treat-
ment skin dose to the calibration point dose, was calcu-
lated from measurements from a MOSFET placed on the
surface of a humanoid phantom (CIRS Inc., Norfolk, VA).
Phantom setup was made identical to the treatment
setup by changing the positions every 60° about the
patient’s longitudinal axis. Eight MOSFETs were at-
tached on the phantom’s surface; at each of four locations
(anterior, posterior, left and right lateral) in both the chest
section and the abdominal section.
Three EBT2 films were inserted in the head, chest,
and abdominal sections of the humanoid phantom to
verify the TSEI commissioning. The film was then scanned
using an Epson 1000X flatbed scanner (Epson America,
Inc. Long Beach, CA) and in-house software was used
to assess the depth dose distribution and isodose curves
within the phantom.
Figure 1 Positions of treatment apparatus gantry used to generate a dual field for the anterior body position in TSEI. The spoiler was
only used for 6 MeV TSEI beam. The gantry angle (θ) was ± 18.5° and 90 ± 18° for 4 MeV with no spoiler and 6 MeV with spoiler, respectively.
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Profile uniformity
The optimized treatment fields were at 90 ± 18.5° and
90 ± 18° for 4 MeV with no spoiler and 6 MeV with
spoiler, respectively. With these dual fields, the results of
profile uniformity are shown in Figure 2. In the vertical
(inferior to superior) profile, uniformity of ±10% was
demonstrated for 4 MeV and 6 MeV TSEI beams up to
the end of the spoiler from 20 cm above the floor. Thus,
a wooden patient support device of 20 cm height was
designed to reduce scatter from the floor, and to indicate
the patient’s treatment positions. The profile variations
of 4 MeV with no a spoiler are much greater than that
of 6 MeV with a spoiler. In the horizontal (left to right)
profile, uniformity of ±10% was demonstrated for 4 MeVFigure 2 Uniform vertical and horizontal profiles for TSEI beams. Prof
(b) are shown.and 6 MeV TSEI beams within 70 cm width. The profiles
for both beams were similar and shaped like a parabola.
PDD and Photon contamination
With TSEI treatment fields, the relative depth dose of
4 MeV electrons was 81.4% at the surface and 100% at
0.4 cm. For 6 MeV electrons, the relative depth dose was
93.4% at the surface and 100% from 0.2 cm to 0.4 cm. The
depth of maximum dose was identical for both TSEI beams
since the maximum energy of 6 MeV electrons attenuated
by the 1 cm spoiler was 4 MeV. The PDD results are shown
in Figure 3. The 4 MeV electrons with no the spoiler had a
maximum penetration depth 1.3 cm. For 6 MeV with the
spoiler, the maximum penetration was 1.9 cm. The mean
energy Ε0 was calculated from R50 according to AAPMiles of TSEI treatment of vertical direction (a) and horizontal direction
Figure 3 Relative depth dose curve for central axis with dual-fields. The STD (standard) beam was from the 100 cm SSD and 10 cone field.
Table 2 MOSFET dose measurement 4 MeV TSEI for
















ANT of Chest 110 201 311 200.8 0.4
Park et al. Radiation Oncology 2014, 9:197 Page 4 of 6
http://www.ro-journal.com/content/9/1/197TG-70 [28]. The mean energy was 2.9 MeV and 3.2 MeV
for 4 MeV and 6 MeV TSEI beams, respectively. For photon
contamination, the ion chamber detected a signal which
was contaminated with some level of noise (<0.001%).
Table 1 is a tabulation of the treatment beam parameters.
Phantom measurements and verification
During one cycle (two treatment days) of TSEI, MOSFET
detectors placed on the surface of the humanoid phantom
were irradiated based on calculated MUs at the calibration
point using the six dual-field technique. The average mea-
sured doses at the eight points were normalized to the pre-
scription dose (200 cGy). Table 2 summarizes the resulting
dose verification for the 4 MeV TSEI beam. The dose
difference was calculated between the normalized dose
and prescription dose. The maximum dose discrepancy
of in-vivo dosimetry was 8.5% higher than the prescrip-
tion dose and within the acceptable tolerance level of
10%. The calculated B-factor of the 4 MeV TSEI beam
was 1.55. Table 3 summarizes the resulting dose verifi-
cation for the 6 MeV TSEI beam. The maximum dose










Standard 4 MeV 1.2 0.6 3.2 1.6 0.3
Standard 6 MeV 2.3 1.3 5.5 2.9 0.6
4 MeV TSEI 0.95 0.4 2.9 1.3 < 0.001
6 MeV TSEI 1.2 0.4 3.2 1.6 < 0.001
Calculated using TG-70: Ε ¼ 0:656 þ 2:059R50 þ 0:022R502.The calculated B-factor of the 6 MeV TSEI beam was
1.53. The B-factors were comparable for both TSEI
beams in this study. Using the B-factor, the treatment
MUs were finally determined for both TSEI beams.
The films inserted in the humanoid phantom were
used for relative dose measurements. The periphery of
the film was uniformly irradiated from the TSEI beams.
PDDs from the irradiated films are shown in Figure 4.
The maximum dose occurred at the surface of the
phantom. At all three parts of the phantom, PDDs of
the 4 MeV TSEI beam were steeper than that of the
6 MeV TSEI beam. The depth at which 80% of the pre-
scribed dose was 0.22 cm for 4 MeV TSEI and average
0.53 cm for 6 MeV TSEI, which was the average depth
of three films. The maximum penetration depth of theRight of Chest 140 168 308 198.9 -0.6
POST of Chest 197 103 300 193.7 -3.1
Light of Chest 135 160 295 190.5 -4.8
ANT of Umbilicus 115 221 336 216.9 8.5
Right of Umbilicus 154 161 315 203.4 1.7
POST of Umbilicus 203 104 307 198.2 -0.9
Light of Umbilicus 151 155 306 197.6 -1.2
Average 309.8 200.0 0.0
First day beams: AP, LPO, and RPO Second day beams: PA, LAO, and RAO.
Table 3 MOSFET dose measurement 6 MeV TSEI for dosimetric commissioning and treatment MUs
Detector location 1st day dose (cGy) 2nd day dose (cGy) Total dose (cGy) Normalized dose (cGy) Dose difference (%)
ANT of Chest 112 106 218 200.7 0.4
Right of Chest 114 194 307 198.0 -1.0
POST of Chest 138 165 303 189.3 -5.4
Light of Chest 185 105 290 202.8 1.4
ANT of Umbilicus 163 147 311 199.4 -0.3
Right of Umbilicus 111 195 305 211.7 5.9
POST of Umbilicus 161 163 324 186.3 -6.8
Light of Umbilicus 178 107 285 211.7 5.9
Average 306.2 200.0 0.0
First day beams : AP, LPO, and RPO Second day beams: PA, LAO, and RAO.
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6 MeV TSEI beams, respectively.
Discussion
The 4 MeV electron beam with no a spoiler was investi-
gated in implementing a clinical TSEI in this study. The
electron measurement at extended SSD has a larger uncer-
tainty and more setup variation than the electron measure-
ment with nominal SSD. Thus, all measurements were
performed three times and the average of the values was
applied in this study.
The comprehensive dosimetric aspects for the 4 MeV
TSEI beam were compared to a nominal 6 MeV TSEI
technique. The dosimetric aspects of the 4 MeV TSEI
beam, such as profile uniformity and relative photon
contamination, were comparable to those of the 6 MeV
TSEI beam, which could be implemented a clinical
treatment. In the PDD, however, 80% of the prescribed
dose was obtained at 0.22 cm depth in humanoid phantomFigure 4 Relative depth dose curve for six-dual fields using film withimeasurements, which was shallower than the epidermis
and dermis locations of 0.5 cm. It is limited to use for large
tumor in T3 stage of CTCLTNM classification.
The required penetration depth is usually thought to
vary with the stage and type of disease and may vary
over the body [29]. It also depends on the part of the
body, the epidermis is thinnest on the eyelids at
0.5 cm, and thickest on the palms and soles at 0.15 cm,
and dermis is 0.03 cm on the eyelid and 0.3 cm on the
back. The 4 MeV TSEI beam could be used for skin
diseases located in shallow depths of less than 0.3 cm.
Moreover, an electron boost was concurrently adminis-
tered to under dosage regions such as the top of the
patient’s head and perineum. The 4 MeV TSEI beam,
therefore, could be also used for the second treatment
course based on region of interest. On the other hand,
increase of total MU causes treatment time to rise and
longer treatment times may give rise to instability of
patient posture.n three section of humanoid phantom.
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The suggested 4 MeV beam for TSEI could be applied to
shallow depth skin diseases and to electron boost as sec-
ond treatment course.
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